EGFR Positivity May Be Poor Predictor of Recurrence in Non-Small Cell Lung Cancer
Despite high rates of recurrence, 37% of patients with stage IB-IIIA NSCLC remained disease-free at 5 years.
Despite high rates of recurrence, 37% of patients with stage IB-IIIA NSCLC remained disease-free at 5 years.
Metformin did not improve progression-free or overall survival in either study.
The study showed differences by cancer type and race/ethnicity.